Obesity Drugs in Development: A brief overview of the pipeline
Obesity and its causes are the focus of extensive research evaluating new therapeutic targets. Get an at-a-glance update on progress and FDA approvals during 2021
Pharmacologic options for obesity management have been limited, but increased understanding of the pathophysiology of the disease of obesity has given rise to promising drug targets and novel therapeutic strategies, according to the authors of a recent review in Endocrine Reviews.
The authors point to a broad range of systems and tissues being investigated as sites of targets for pharmacotherapy including the central nervous system, gastrointestinal hormones, adipose tissue, kidney, liver, and skeletal muscle.
Scroll through the slides below for concise summaries of new obesity drugs under investigation and coming into play in 2021.
